Xiaochun F. Dong

Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 63 publications

A 5-Azetidinyl BODIPY-Olaparib Conjugate for PARP-Targeted Nuclear and Orthotopic Oral Tumor Imaging.

A 5-Azetidinyl BODIPY-Olaparib Conjugate for PARP-Targeted Nuclear and Orthotopic Oral Tumor Imaging.

Journal: ChemMedChem

Published: June 16, 2026

Novel boron-modified aza-BODIPY photosensitizers for low-dose light-dependent anti-cancer photodynamic therapy.

Novel boron-modified aza-BODIPY photosensitizers for low-dose light-dependent anti-cancer photodynamic therapy.

Journal: European journal of medicinal chemistry

Published: May 19, 2025

Design, Synthesis, and Evaluation of Boron Dipyrromethene-Based Fluorescent Probes Targeting BRAF for Melanoma Diagnosis.

Design, Synthesis, and Evaluation of Boron Dipyrromethene-Based Fluorescent Probes Targeting BRAF for Melanoma Diagnosis.

Journal: ChemMedChem

Published: February 04, 2025

Synthesis and evaluation of a novel BODIPY fluorescent probe targeting integrin αvβ3 for cancer diagnosis.

Synthesis and evaluation of a novel BODIPY fluorescent probe targeting integrin αvβ3 for cancer diagnosis.

Journal: European journal of medicinal chemistry

Published: August 24, 2024

Synthesis and Photodynamic Activities of Pyridine- or Pyridinium-Substituted Aza-BODIPY Photosensitizers.

Synthesis and Photodynamic Activities of Pyridine- or Pyridinium-Substituted Aza-BODIPY Photosensitizers.

Journal: Journal of medicinal chemistry

Published: August 21, 2024

Compound Z526 alleviates chemotherapy-induced cachectic muscle loss by ameliorating oxidative stress-driven protein metabolic imbalance and apoptosis.

Compound Z526 alleviates chemotherapy-induced cachectic muscle loss by ameliorating oxidative stress-driven protein metabolic imbalance and apoptosis.

Journal: European journal of pharmacology

Published: December 21, 2023

Lysosome-targeted Aza-BODIPY photosensitizers for anti-cancer photodynamic therapy.

Lysosome-targeted Aza-BODIPY photosensitizers for anti-cancer photodynamic therapy.

Journal: Bioorganic & medicinal chemistry

Published: October 30, 2023

Novel oral compound Z526 mitigates cancer-associated cachexia via intervening NF-κB signaling and oxidative stress.

Novel oral compound Z526 mitigates cancer-associated cachexia via intervening NF-κB signaling and oxidative stress.

Journal: Genes & diseases

Published: August 02, 2023

A collagen-binding SIRPαFc fusion protein for targeted cancer immunotherapy.

A collagen-binding SIRPαFc fusion protein for targeted cancer immunotherapy.

Journal: International immunopharmacology

Published: July 05, 2023

Meso pyridinium BODIPY-based long wavelength infrared mitochondria-targeting fluorescent probe with high photostability.

Meso pyridinium BODIPY-based long wavelength infrared mitochondria-targeting fluorescent probe with high photostability.

Journal: Analytical methods : advancing methods and applications

Published: June 19, 2023

Discovery of Subcellular-Targeted Aza-BODIPY Photosensitizers for Efficient Photodynamic Antitumor Therapy.

Discovery of Subcellular-Targeted Aza-BODIPY Photosensitizers for Efficient Photodynamic Antitumor Therapy.

Journal: Journal of medicinal chemistry

Published: May 19, 2023

Selection of an aggregation-caused quenching-based fluorescent tracer for imaging studies in nano drug delivery systems.

Selection of an aggregation-caused quenching-based fluorescent tracer for imaging studies in nano drug delivery systems.

Journal: Nanoscale

Published: May 09, 2023

Showing 1-12 of 63

Last Updated: 09/26/2026